Top

Published in:

01-09-2008 | Original Article

New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer

Authors: Hiroyuki Murota, Yorihisa Kotobuki, Noriko Umegaki, Mamori Tani, Ichiro Katayama

Published in: Rheumatology International | Issue 11/2008

Abstract

It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of the ulcer region. It also suggested that Lipo-PGE1 has the effect of maintaining an appropriate balance of induction of inflammation and angiogenesis. Additionally, it revealed that Lipo-PGE1 controls the production of cytokines, which are associated with the growth of collagen diseases. From these results, it can be expected that Lipo-PGE1 will act favorably on intractable collagen diseases.

Yamaguchi Y, Yoshikawa K (2001) Cutaneous wound healing: an update. J Dermatol 28:521–534PubMed

Cianfarani F, Tommasi R, Failla CM, Viviano MT, Annessi G, Papi M, Zambruno G, Odorisio T (2006) Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endtherial growth factor transcription in the ulcer bed. Br J Dermatol 154:34–41PubMedCrossRef

Lauer G, Sollberg S, Colo M, Flamme I, Sturzebecher J, Mann K, Krieg T, Eming SA (2000) Expression and proteolysis of vascular endtherial growth factor is increased in chronic wounds. J Invest Dermatol 115:12–18PubMedCrossRef

Papps PJ, Fallek SR, Gracia A, Anaki CT, Back TL, Duran WK, Hobson RW 2nd (1995) Role of leukocyte activation in patients with venous stasis ulcers. J Surg Res 59:553–559CrossRef

Frenkel O, Shani E, Ben-Bassat I, Brok-Simoni F, Rozenfeld-Granot G, Kajakaro G, Rechavi G, Amariglio N, Shinar E, Danon D (2002) Activated macrophages for treating skin ulceration:gene expression in human monocytes after hypo-osmotic shock. Clin Exp Immunol 128:59–66PubMedCrossRef

Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G (1989) Dual contorol of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773–3779PubMed

Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD (1991) A form of circulating ICAM-1 in human serum. J Immunol 147:3788–3793PubMed

Hahn J, Junger M, Friedrich B, Zuder D, Steins A, Hahn M, Klyscz T (1997) Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency. Vasa 26:277–281PubMed

Rowe IF, Deans AC (1986) Serum C-reactive protein measurement in pyoderma gangreosom. Dermatologica 173:216–219PubMed

10.

Heshmat NM, EL-Kerdanv TH (2007) Serum levels of vascular endothrial growth factor in children and adolescents with systemic lupus erythematosus. Pediatr Allergy Immunol 18:346–353PubMedCrossRef

11.

Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothrial growth factor in collagen diseases. Br J Dermatol 139:1049–1051PubMedCrossRef

12.

Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF (1994) Vascular permeability factor/endothrial growth factor (VPF/VEGF) accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346PubMedCrossRef

13.

Murphy MA, Jovce WP, Condron C, Bouchier-Haves D (2002) A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. Eur J Vasc Endovasc Surg 23:349–352PubMedCrossRef

14.

Drinkwater SL, Burnand KG, Ding R, Smith A (2003) Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg. 38:1106–1112PubMedCrossRef

15.

Aoki S, Imai K, Yachi A (1993) Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 38:485–490PubMedCrossRef

16.

Machold KP, Kiener HP, Graninger W, Graninger WB (1993) Soluble intercellular adhesion molecule-1(ICAM-1) in patients with rheumatoid arthritis and systemic lupus erthmatosus. Clin Immunol Immunopathol 68:74–78PubMedCrossRef

17.

Cush JJ, Rothlein R, Lindslev HB, Mainolfi EA, Lipskv PE (1993) Increased levels of circulating intercellular adhesion molecute 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 36:1098–1102PubMedCrossRef

18.

Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GO (1993) Circulating intercellular adhesion molecute-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88–92PubMedCrossRef

19.

Kiener H, Graninger W, Machold K, Aringer M, Graninger WB (1994) Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 12:483–487PubMed

20.

Murota H, Muroi E, Yamaoka T, Hamasaki Y, Katayama I (2006) Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis. Allergol Int 55:199–202PubMedCrossRef

21.

Mizushima Y, Yanagawa A, Hoshi A (1983) Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 35:666–667PubMed

22.

Tsutsui K, Shirasaki F, Takata M, Takehara K (1996) Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. Dermatology 192:120–124PubMedCrossRef

Title: New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer
Authors: Hiroyuki Murota
Yorihisa Kotobuki
Noriko Umegaki
Mamori Tani
Ichiro Katayama
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 11/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0589-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2008

Association between ‘interleukin’ 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement

Systemic lupus erythematosus, celiac disease and antiphospholipid antibody syndrome: a rare association

Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis

Leukocytapheresis for the treatment of refractory Henoch–Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy

Assessing disability in patients with rheumatic diseases: translation, reliability and validity testing of a Greek version of the Stanford Health Assessment Questionnaire (HAQ)

The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page